Anidulafungin Accord

What Is Anidulafungin Accord and What Is It Used For?

Anidulafungin Accord contains the active substance anidulafungin, an echinocandin antifungal used to treat invasive candidiasis — a serious fungal infection of the bloodstream and internal organs caused by Candida yeast species. It is approved for adults and pediatric patients aged 1 month to under 18 years.

Invasive candidiasis is a life-threatening systemic infection that occurs when Candida organisms enter the bloodstream (candidemia) or spread to deep tissues and organs. This condition predominantly affects critically ill patients in intensive care units, individuals who are immunocompromised, those who have undergone major surgery, or patients with central venous catheters. Without appropriate treatment, invasive candidiasis carries a mortality rate of 30–60%, making prompt and effective antifungal therapy essential.

Anidulafungin belongs to the echinocandin class of antifungal agents, which are considered first-line therapy for invasive candidiasis according to both the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). The echinocandin class includes three agents — anidulafungin, caspofungin, and micafungin — all of which target the same enzyme but differ in their pharmacokinetic properties and metabolism.

The mechanism of action of anidulafungin involves non-competitive inhibition of 1,3-beta-D-glucan synthase, an enzyme that is essential for the synthesis of the fungal cell wall. Beta-glucan is a major structural component of the Candida cell wall, accounting for approximately 30–60% of the wall's dry weight. When glucan synthesis is inhibited, the fungal cell develops an incomplete or defective cell wall, rendering it osmotically fragile. This leads to cell lysis and death. Because human cells do not have cell walls or glucan synthase, anidulafungin exhibits excellent selectivity for fungal cells with minimal toxicity to human tissues.

Anidulafungin demonstrates potent fungicidal activity against most Candida species, including Candida albicans, C. glabrata, C. tropicalis, C. krusei, and C. parapsilosis, although minimum inhibitory concentrations (MICs) tend to be higher for C. parapsilosis. This broad spectrum makes it a valuable tool in the treatment of invasive candidiasis, where the causative species may not be immediately known at the time treatment must be initiated.

What Should You Know Before Taking Anidulafungin Accord?

Anidulafungin Accord must not be used if you are allergic to anidulafungin, other echinocandins (e.g., caspofungin, micafungin), or any of the excipients. Your doctor will monitor your liver function and watch for signs of allergic or infusion-related reactions during treatment.

Contraindications

The primary contraindication for Anidulafungin Accord is a known hypersensitivity to anidulafungin, other echinocandins (such as caspofungin or micafungin), or any of the excipients in the formulation. Cross-reactivity between echinocandins has been reported, so patients who have experienced an allergic reaction to any echinocandin should not receive anidulafungin. Additionally, patients with hereditary fructose intolerance must not use this medication, as each vial contains 102.5 mg of fructose.

Before initiating treatment, your healthcare team will obtain a thorough medical history including any previous reactions to antifungal medications, particularly echinocandins. They will also review your complete medication list to identify any potential interactions, assess your liver and kidney function, and evaluate your overall clinical status.

Warnings and Precautions

Several important clinical considerations apply during treatment with anidulafungin:

• Hepatic effects: Elevated liver enzymes and hepatic abnormalities have been reported. Your doctor will monitor liver function tests regularly throughout treatment. If clinically significant liver function abnormalities develop, the risks and benefits of continuing therapy should be carefully reassessed.
• Infusion-related reactions: These may include rash, urticaria (hives), flushing, pruritus (itching), bronchospasm, and dyspnea (difficulty breathing). To minimize these reactions, the infusion rate must not exceed 1.1 mg/min. If reactions occur, the infusion should be slowed or temporarily interrupted.
• Allergic reactions: Life-threatening allergic reactions, including anaphylaxis, have been reported rarely. Patients should be monitored during and after infusion for signs of hypersensitivity. Healthcare professionals should be prepared to manage anaphylaxis if it occurs.
• Anesthesia: If you are receiving general anesthesia while being treated with anidulafungin, your anesthesiologist should be informed, as histamine-mediated symptoms (including bronchospasm, facial flushing, and hypotension) have been reported.

Pregnancy and Breastfeeding

The effects of anidulafungin during pregnancy have not been adequately studied in humans. Animal studies have shown some evidence of developmental toxicity at high doses, but the relevance of these findings to human pregnancy is uncertain. As a precautionary measure, Anidulafungin Accord is not recommended during pregnancy unless the potential benefit to the mother clearly outweighs the potential risk to the fetus.

Women of childbearing potential should use effective contraception during treatment with anidulafungin. If you become pregnant while receiving this medication, contact your doctor immediately so that the risks and benefits can be reassessed.

It is not known whether anidulafungin or its metabolites are excreted in human breast milk. A decision must be made whether to discontinue breastfeeding or to discontinue therapy, taking into account the benefit of breastfeeding for the child and the benefit of treatment for the mother. Discuss the options with your healthcare provider before starting treatment.

Special Populations and Excipient Warnings

Fructose content: Each vial of Anidulafungin Accord contains 102.5 mg of fructose. Patients with hereditary fructose intolerance (HFI), a rare inherited metabolic disorder, must not receive this medication. Individuals with HFI cannot properly metabolize fructose, which can lead to hypoglycemia, liver damage, and potentially fatal metabolic acidosis. If you or your child cannot consume sweet foods or drinks without experiencing nausea, vomiting, bloating, cramps, or diarrhea, inform your doctor before receiving this medicine.

Sodium content: This medicinal product contains less than 1 mmol (23 mg) sodium per dose, meaning it is essentially sodium-free. This is relevant for patients on a sodium-restricted diet.

Pediatric use: Anidulafungin Accord is approved for use in children aged 1 month to less than 18 years. It should not be given to neonates younger than 1 month of age, as safety and efficacy data in this population are insufficient.

How Does Anidulafungin Accord Interact with Other Drugs?

Anidulafungin has minimal drug interactions because it is not metabolized by cytochrome P450 enzymes and does not undergo hepatic metabolism. In vitro studies and clinical pharmacokinetic analyses have shown no clinically significant interactions with commonly co-administered medications.

One of the distinguishing pharmacokinetic features of anidulafungin is its unique degradation pathway. Unlike other antifungal agents (and indeed most drugs), anidulafungin is not metabolized by hepatic enzymes. Instead, it undergoes slow chemical degradation to an open-ring peptide at physiological temperature and pH. This unusual pathway means that anidulafungin does not interact with the cytochrome P450 (CYP) enzyme system, glucuronidation pathways, or drug transporters such as P-glycoprotein.

Clinical drug interaction studies have been conducted with several commonly co-administered medications in critically ill patients. The results are summarized in the table below. In general, no dose adjustments are required when anidulafungin is administered alongside other medications. However, you should always inform your healthcare provider about all medications you are currently taking, including prescription drugs, over-the-counter medicines, and herbal supplements.

The favorable drug interaction profile of anidulafungin makes it a particularly useful antifungal in critically ill patients who are typically receiving multiple concurrent medications, including immunosuppressants, antibiotics, antiviral agents, and sedatives. This advantage is often cited by clinical guidelines when recommending echinocandins as first-line therapy for invasive candidiasis in complex patients.

What Is the Correct Dosage of Anidulafungin Accord?

Anidulafungin Accord is administered as a slow intravenous infusion once daily. Adults receive a 200 mg loading dose on day 1 followed by 100 mg daily. Pediatric dosing is weight-based: 3 mg/kg loading dose (max 200 mg) followed by 1.5 mg/kg daily (max 100 mg). The infusion rate must not exceed 1.1 mg/min.

Anidulafungin Accord will always be prepared and administered by a healthcare professional in a clinical setting. The powder must first be reconstituted with water for injection and then further diluted with either 0.9% sodium chloride or 5% glucose solution before infusion. The drug is never given as a bolus injection and must be infused slowly to minimize the risk of infusion-related reactions.

Adults

Children and Adolescents (1 month to <18 years)

For pediatric patients, the volume of infusion solution varies depending on the patient's body weight. The reconstituted solution must be further diluted to a final concentration of 0.77 mg/ml. Healthcare professionals will calculate the required volumes based on the child's weight using the following formulas:

1. Volume of reconstituted anidulafungin (ml) = dose (mg) ÷ 3.33 mg/ml
2. Total volume of dosing solution (ml) = dose (mg) ÷ 0.77 mg/ml
3. Volume of diluent (ml) = total volume of dosing solution − volume of reconstituted anidulafungin

Elderly Patients

No dose adjustment is required for elderly patients. Clinical studies have included patients over 65 years of age, and no significant differences in safety or efficacy were observed compared to younger adults. However, elderly patients may have reduced hepatic and renal function, and clinical response should be monitored carefully.

Missed Dose

Because anidulafungin is administered in a hospital setting under medical supervision, it is unlikely that a dose would be missed. However, if a dose is inadvertently omitted, a double dose must not be given. Instead, the normal daily dose should be resumed as soon as possible, and the treating physician should be notified to determine if any adjustments to the treatment plan are necessary.

Overdose

In clinical trials, single doses of up to 400 mg have been administered without dose-limiting toxicity. There is no specific antidote for anidulafungin overdose. Anidulafungin is not dialyzable, meaning hemodialysis will not effectively remove it from the body. In the event of an overdose, treatment should be supportive, with monitoring for adverse reactions and management of symptoms as they arise. If you suspect an overdose or have any concerns, contact your healthcare team immediately.

Duration of Treatment

The duration of antifungal treatment for invasive candidiasis is individualized based on the patient's clinical and microbiological response. As a general guideline, treatment should continue for at least 14 days after the last positive blood culture for Candida. Your physician will make follow-up blood cultures and clinical assessments to determine when it is safe to discontinue therapy. After completing IV anidulafungin treatment, your doctor may prescribe an oral antifungal agent (step-down therapy) to continue treatment or to prevent relapse.

What Are the Side Effects of Anidulafungin Accord?

Like all medications, anidulafungin can cause side effects, although not everyone experiences them. The most common side effects are low potassium levels (hypokalemia), diarrhea, and nausea. Serious but rare side effects include life-threatening allergic reactions and significant liver abnormalities.

Side effects observed during clinical trials and post-marketing surveillance are categorized below by frequency. It is important to note that many of the reported side effects occurred in critically ill patients with multiple underlying conditions and concurrent medications, making it challenging to attribute specific effects solely to anidulafungin.

If you experience any side effects, including those not listed above, talk to your doctor, pharmacist, or nurse. You can also report suspected side effects to your national pharmacovigilance authority (e.g., the FDA MedWatch program in the United States, the Yellow Card Scheme in the United Kingdom, or the EMA in the European Union). Reporting helps regulatory agencies continuously monitor the benefit-risk balance of medicines.

How Should You Store Anidulafungin Accord?

Unopened vials of Anidulafungin Accord should be stored in a refrigerator at 2–8°C. After reconstitution, the solution may be stored at up to 25°C for up to 24 hours. The final diluted infusion solution may be stored at room temperature (25°C) for up to 48 hours and must not be frozen.

Proper storage of anidulafungin is critical to ensuring its stability and efficacy. As this medication is prepared and administered in a hospital pharmacy or clinical setting, storage is managed by healthcare professionals. However, it is important that patients understand the general storage requirements:

• Unopened vials: Store in a refrigerator at 2–8°C (36–46°F). Keep out of the reach of children.
• Reconstituted concentrate: May be stored at up to 25°C (77°F) for up to 24 hours before further dilution. From a microbiological standpoint, it should ideally be used immediately.
• Final infusion solution: May be stored at 25°C (room temperature) for up to 48 hours. Must not be frozen. Should be administered at room temperature within 48 hours of preparation.
• Do not use after the expiration date printed on the label and carton. The expiration date refers to the last day of the stated month.
• Disposal: Do not dispose of medications via wastewater or household waste. Return unused medication to a pharmacy or healthcare facility for proper disposal according to local regulations.

Healthcare professionals should visually inspect the reconstituted and diluted solutions for particulate matter and discoloration before administration. If particles or discoloration are observed, the solution should be discarded. From a microbiological perspective, if the product is not used immediately after reconstitution or dilution, storage times and conditions are the responsibility of the user and should normally not exceed 24 hours at 2–8°C unless reconstitution and dilution were performed under controlled and validated aseptic conditions.

What Does Anidulafungin Accord Contain?

Each vial contains 100 mg of anidulafungin as the active substance. The reconstituted solution has a concentration of 3.33 mg/ml, and the final diluted infusion solution has a concentration of 0.77 mg/ml. The excipients include fructose, mannitol, polysorbate 80, lactic acid, sodium hydroxide, and hydrochloric acid.

Active Ingredient

The active substance is anidulafungin, a semi-synthetic echinocandin lipopeptide produced by chemical modification of echinocandin B, a natural product of the fungus Aspergillus nidulans. Each vial contains 100 mg of anidulafungin as a white to off-white lyophilized powder or cake.

Inactive Ingredients (Excipients)

• Fructose — 102.5 mg per vial (see warnings regarding hereditary fructose intolerance)
• Mannitol — a sugar alcohol used as a bulking agent in the lyophilized formulation
• Polysorbate 80 — a non-ionic surfactant that aids in solubilization
• Lactic acid — used for pH adjustment
• Sodium hydroxide — used for pH adjustment
• Hydrochloric acid — used for pH adjustment

Packaging

Anidulafungin Accord is supplied as a single vial containing 100 mg of powder for concentrate for solution for infusion, packaged in a carton. The powder appears as a white to off-white cake or powder. The product is for single use only; any unused medicinal product or waste material should be disposed of in accordance with local requirements.

Frequently Asked Questions About Anidulafungin Accord